Detalhe da pesquisa
1.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Hepatology
; 67(2): 505-513, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28865152
2.
Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A.
Bioorg Med Chem Lett
; 23(12): 3627-30, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23642966
3.
Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.
Bioorg Med Chem Lett
; 22(6): 2212-5, 2012 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22342631
4.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
J Gastroenterol
; 53(4): 557-565, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948366
5.
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
J Gastroenterol
; 53(5): 689, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29134328
6.
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
J Gastroenterol
; 53(4): 566-575, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29052790
7.
Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
Antimicrob Agents Chemother
; 51(6): 1889-96, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17371824
8.
Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
Antimicrob Agents Chemother
; 51(12): 4290-6, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17908950
9.
Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Antimicrob Agents Chemother
; 48(6): 2260-6, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15155230